

Montreal, October 6, 2020

Dear Investigator,

We would like to bring to your attention that the LDI, in coordination with McGill University and its affiliated Institutions, has started the process of rolling-out Stage 3 of the Canada Research Continuity Emergency Fund (CRCEF). You should have received by now, from McGill directly, several communications in this regard. For your convenience, we are attaching a copy of those communications. McGill is holding a Virtual Town Hall meeting on October 13th to discuss the details of this program and we encourage you to participate by confirming your attendance by October 7th through the following link:

<https://www.mcgill.ca/research/channels/event/town-hall-canada-research-continuity-emergency-fund-crcef-324745>

More details about the CRCEF can be found at:

<https://www.mcgill.ca/research/research/funding/federal/crcef>

<https://www.sshrc-crsh.gc.ca/funding-financement/crcef-fucrc/>

We urge you to read the full details of Stage 3 expense eligibility and to regularly check for updates as more clarifications become available.

While Stage 1 was targeted at salaries and stipends paid from non-governmental sources, Stage 3 allows for claims against a much broader source of research funding (e.g., start-up funds, Tri-Agency funding, NIH and other non-Canadian funding, industry, foundations) for expenses related to the maintenance and ramp-up of research activities.

Only direct costs of research that are extraordinary and incremental to those already covered by existing sources of funds and have been incurred between March 15 and November 15, 2020 will be reimbursed, at up to 75% depending on the funds available and the scope of expenses requested.

Extraordinary incremental costs are defined as unanticipated additional costs that would not normally have been incurred in the absence of the COVID-19 pandemic and cannot be funded by existing sources of funds.

Applicants must justify the need for the funds based on actual costs **incurred** between March 15 and November 15, 2020. Eligible expenses include costs associated with the following categories:

a) Maintenance costs:

- Animal and specimen care through the crisis period;
- Maintenance of equipment, software, cohorts, datasets, including warranties, licenses and service contracts;
- Technological equipment for remote access to maintain assets
- Other additional costs incurred as a consequence of the lockdown (the list is not exhaustive):
 - Uber/Taxi fare for essential personnel to travel to the LDI
 - Costs associated with the purchasing of licenses to allow your team to work remotely.

b) Ramp-up costs:

- Re-organizing the research environment and activities;
- additional costs to bring the research closer to the pre-pandemic level, including experiments or related to the restart of collections and datasets (e.g., population-based, environmental);
- User fees charged by shared platforms to researchers to restart research activities (e.g., animal-care facilities, digital labs);
- Re-scheduling and restarting human and clinical trials;
- Exceptional costs to access special facilities, shared platforms and resources, knowledge transfer meetings and workshops;
- restarting, reassembling and safety checks of equipment and facilities;
- Reacquiring lost and donated laboratory and field supplies and equipment, reagents, perishable materials, laboratory animal and other living specimens; and
- Personal protective equipment and related items for research personnel.

To facilitate the process, we will use the sample template developed by McGill. The LDI finance department will be sending you this template with the details and amounts of your more visible expenses (i.e: expenses incurred to maintain the animal colony, core facilities, services contracts, etc.). If you have other expenses that you would consider eligible for this program, please include them on the same file and send them back to Gustavo Wendichansky at gustavo.wendichansky@ladydavis.ca with proper justification by October 30th.

If you have any questions in regards to the process of eligibility of expenses under this program, please contact Gustavo Wendichansky or Michel Fima directly at

- gustavo.wendichansky@ladydavis.ca / ext.: 28252
- michel.fima@ladydavis.ca / ext.: 24669

The LDI is committed to advancing equity, diversity and inclusion in research, including equitable access to funding opportunities like the CRCEF. If any principal investigator is unsure of eligibility for CRCEF or needs additional support, please do not hesitate to send inquiries to any of the members of the CRCEF steering committee: Rod McInnes / Koren Mann / Josie Ursini-Siegel / Yvhans Chery/ Gustavo Wendichansky.

Sincerely,



Gustavo Wendichansky
Chief Operating & Financial Officer
Lady Davis Institute – SMBD Jewish General Hospital
T: 514-340-8252
e-mail: gustavo.wendichansky@ladydavis.ca